In the article “177Lu-PSMA Radioligand Therapy for Prostate Cancer” by Fendler et al. (J Nucl Med. 2017;58:1196–1200), the “Indication” section incorrectly states that 177Lu-PSMA RLT may be considered in patients with sufficient bone marrow reserve as defined by a white blood cell count lower than 3,000/μL and a platelet count lower than 75,000/μL. The correct levels are higher than 3,000/μL and higher than 75,000/μL, respectively. We regret the error.
- © 2018 by the Society of Nuclear Medicine and Molecular Imaging.